The termination removes a major source of potential future revenue and de-risks Rigel's pipeline, which was dependent on Lilly's development efforts. Traders should assess whether Rigel can independently advance the RIPK1 programs and consider the impact on the company's valuation, particularly given its $600M market cap.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $30.47entry
- T+1 · 7mo ago +0.82%α +1.21% · $30.72
- T+5 · 7mo ago −4.30%α −4.35% · $29.16
- T+20 · 6mo ago −7.12%α −10.29% · $28.30
- T+60 · 4mo ago +33.05%α +28.27% · $40.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rigel Pharmaceuticals announced that Eli Lilly has elected to terminate their 2021 License and Collaboration Agreement, effective June 15, 2026. The agreement covered the development and commercialization of ocadusertib and other RIPK1 inhibitors. Rigel will regain full rights but does not expect future milestones or royalties.
Key Facts
- Eli Lilly terminated the License and Collaboration Agreement dated February 18, 2021
- Termination becomes effective on June 15, 2026
- Agreement covered ocadusertib (R552) and other RIPK1 inhibitors for CNS and non-CNS diseases
- Rigel will regain full rights to the licensed compounds
- Company does not expect to receive future milestones or royalties under the agreement
Financial Impact
Loss of potential future milestone payments and royalties from Lilly; no further revenue expected from the collaboration
Risk Factors
- Loss of development funding and commercialization expertise from Lilly
- Uncertainty around Rigel's ability to independently develop and fund the RIPK1 programs
- Downward pressure on valuation due to lost future royalty stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000027 |
| Document: 0001034842-26-000027-index.html | 0001034842-26-000027 |
| Document: 0001034842-26-000027.txt | 0001034842-26-000027 |
Track record
12 reports on RIGL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers